Hematology Department Of The 920th Hospital
Clinical trials sponsored by Hematology Department Of The 920th Hospital, explained in plain language.
-
Triple therapy aims to overcome antibody barrier in Half-Matched stem cell transplants
Disease control Not yet recruitingThis study tests whether a combination of dexamethasone, intravenous immunoglobulin (IVIG), and extra donor immune cells can safely lower harmful antibodies that attack donor stem cells in half-matched (haploidentical) transplants. The trial enrolls 60 adults aged 18–65 with bloo…
Phase: PHASE2 • Sponsor: Hematology department of the 920th hospital • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Could a Two-Week chemo blast be just as good as three for AML?
Disease control Not yet recruitingThis study tests whether a two-week course of the VA-CAG chemotherapy works as well as the usual three-week course for adults newly diagnosed with acute myeloid leukemia (AML). About 110 participants will be randomly assigned to one of the two schedules. The goal is to see if the…
Phase: PHASE2 • Sponsor: Hematology department of the 920th hospital • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC